Home Alzheimer’s Disease Pembrolizumab Induces Significantly Improved PFS in MSI-H/dMMR Colorectal Cancer

Pembrolizumab Induces Significantly Improved PFS in MSI-H/dMMR Colorectal Cancer

The phase III KEYNOTE-177 trial designed to evaluate first-line pembrolizumab (Keytruda) in patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic advanced colorectal cancer met 1 of its dual primary endpoints of progression-free survival (PFS), according to Merck, the agent’s developer.

Based on an interim analysis conducted by an independent data monitoring committee (DMC), pembrolizumab monotherapy was found to demonstrate a statistically significant and clinically meaningful improvement in PFS compared with chemotherapy. 

The company indicated that they will be presenting data from this study at an upcoming medical congress. 

“These head-to-head data with Keytruda are the first time a single-agent, anti-cancer therapy, and particularly an anti-PD-1 monotherapy, achieved a statistically significant improvement in…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

32 year old singer Tom Parker of The Wanted diagnosed with stage 4 glioblastoma

submitted by /u/Jexlan Continue Reading to the Source

Recent Comments